Minaris Regenerative Medicine and the U.S. and U.K. operations of WuXi Advanced Therapies have been combined to form Minaris Advanced Therapies, a global cell therapy CDMO and testing partner.
The new company, which was unveiled at the annual ISCT conference in New Orleans, will be headquartered in Philadelphia, Pennsylvania.
With more than 25 years of cell therapy CDMO experience and over 40 years of experience in biosafety testing and product characterization, the new company will support the next wave of commercial cell therapies. Minaris Advanced Therapies brings together:
- More than 1,400 employees specializing in process and analytical development, manufacturing, quality control, quality assurance and regulatory compliance
- Facilities at six sites on three continents, totaling more than 730,000 square feet of infrastructure
- 42 clean rooms for commercial use in Pennsylvania, New Jersey, Germany and Japan
The new company was created from two strategic acquisitions made by U.S. private equity firm Altaris. The firm acquired Minaris Regenerative Medicine from Resonac in September 2024 and the U.S. and U.K. operations of WuXi AppTec’s Advanced Therapies Unit in December 2024.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!